FDA panel gives nod to Hologic tomosynthesis PMA

An advisory panel of the U.S. Food and Drug Administration today unanimously approved a premarket approval (PMA) application from Hologic for a digital breast tomosynthesis (DBT) system. If the FDA signs off on the final PMA, Hologic will be the first vendor to sell a DBT system on the U.S. market.

Click here to read the rest of the article.